Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Jul 31;20(7):e0329000.
doi: 10.1371/journal.pone.0329000. eCollection 2025.

Renal cancer survival in clear cell renal cancer compared to other types of tumor histology: A population-based cohort study

Teesi Sepp  1   2 , Antti Poyhonen  3 , Anneli Uusküla  4 , Andres Kotsar  5 , Thea Veitonmäki  6 , Teuvo L J Tammela  6   7 , Aleksei Baburin  4   8 , Teemu J Murtola  6   7
Affiliations
Comparative Study

Renal cancer survival in clear cell renal cancer compared to other types of tumor histology: A population-based cohort study

Teesi Sepp et al. PLoS One. .

Erratum in

Abstract

Introduction: Renal cancer (RC) presents a challenge with increasing incidence and mortality. This study compares RC cancer-specific survival (CSS) and overall survival (OS) based on histological type.

Study design: This population-based retrospective cohort study covers 1995-2017, utilizing cases from the Finnish Cancer Registry. Comorbidity, procedure and treatment information from 1995-2018 were obtained from the national health care registry, while death data originated from the national death certificate registry. RC cases were categorized by histology to analyze CSS and OS via Fine and Gray's proportional sub-hazards model and Cox regression (adjusting for age, tumor extent, Charlson comorbidity index and treatment).

Results: The final cohort included 14,413 patients, predominantly ccRCC (75.5%), followed by papillary RCC (pRCC),5.8% and chromophobe RCC (chRCC) 2.1%. Univariate analysis showed better OS for non-ccRCC patients, with 5-year survival (5ySR) of 72.6% (95% CI 70.3-74.7%), compared to ccRCC (62.7%, 95%CI 61.8-63.5). Among non-ccRCC, the 5ySRs were as follows: pRCC 74.3% (95%CI 71.2-77.2), chRCC 82.2% (95% CI 77.2-86.1), sarcomatoid variants (sarcRC) 29.2% (95% CI 20.6-38.3), and collecting duct carcinoma (CDC) 23.5% (95%CI 7.3-44.9). Non-ccRCC showed improved CSS compared to ccRCC (sHR 0.69, 95% CI 0.60-0.78). Favorable CSS for chRCC (sHR 0.28, 95% CI 0.18-0.43) and pRCC (sHR 0.66, 95% CI 0.56-0.78), while sarcRC (sHR 1.83, 95% CI 1.36-2.46) and CDC (sHR 3.19, 95% CI 2.01-5.08) showed poorer CSS. Overall, non-ccRCC had a better prognosis, driven by pRCC and chRCC, whereas sarcRC and CDC had poor prognoses. CSS has improved over time, with a 62% reduction in death risk since 1995.

Conclusion: Our results demonstrate that the histological subtype is a powerful predictor of survival. Histology should be used more in clinical decision-making. Having a histological confirmation would tailor the selection of treatment: surgical management for aggressive and ccRCC and conservative management for less aggressive histological types.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow Chart for Formation of the Population-based Cohort of 14,593 Renal.
Fig 2
Fig 2. Kaplan-Meier Curves for Overall Survival for ccRCC and non-ccRCC Subgroups combined.
Fig 3
Fig 3. Kaplan-Meier Curves for Overall Survival for ccRCC and non-ccRCC Subgroups Separated.
Fig 4
Fig 4. Renal Cancer-Specific Survival for ccRCC and non-ccRCC Subgroups Combined.
Fig 5
Fig 5. Renal Cancer-Specific Survival for ccRCC and non-ccRCC Subgroups Separated.
Fig 6
Fig 6. Renal Cancer (all types combined) Cancer-Specific Survival by Period (1995-1999, 2000–2004, 2005–2009, 2010–2014, 2015–2017) (reference – period 1995–1999).
Fig 7
Fig 7. Clear-cell Renal Cancer Cancer–Specific Survival by Period (1995-1999, 2000-2004, 2005–2009, 2010–2014, 2015–2017) (reference – period 1995–1999).
Fig 8
Fig 8. Non-clear-cell Renal Cancer (combined of chromophobe RCC, papillary RCC andother known variants) Cancer-Specific Survival by Period (1995–2004, 2005–2017) (reference – period 1995–1999).
Fig 9
Fig 9. Non-clear-cell Renal Cancer (all variants combined) Cancer-Specific Survival by Period (1995–2004, 2005–2017) (reference – period 1995–1999).
See this image and copyright information in PMC

References

    1. European cancer information system. Europa.eu. Published October 19, 2017. [cited September 19, 2023]. Available from: https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-AE28E$4-1,2$3-All$6-0,...
    1. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2024. , [cited 12 September 2024]. Available from: https://gco.iarc.who.int/today
    1. Bertuccio P, Santucci C, Carioli G, Malvezzi M, La Vecchia C, Negri E. Mortality Trends from Urologic Cancers in Europe over the Period 1980-2017 and a Projection to 2025. Eur Urol Oncol. 2021;4(5):677–96. doi: 10.1016/j.euo.2021.05.005 - DOI - PubMed
    1. Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519–30. doi: 10.1016/j.eururo.2014.10.002 - DOI - PubMed
    1. Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of Renal Cell Carcinoma. Eur Urol. 2019;75(1):74–84. doi: 10.1016/j.eururo.2018.08.036 - DOI - PMC - PubMed

Publication types